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Abstract
Dynamic treatment regimens (DTRs) are sequential decision rules tailored at each
stage by potentially time-varying patient features and intermediate outcomes observed in
previous stages. The complexity, patient heterogeneity and chronicity of many diseases
and disorders call for learning optimal DTRs which best dynamically tailor treatment
to each individual’s response over time. Proliferation of personalized data (e.g., genetic
and imaging data) provides opportunities for deep tailoring as well as new challenges
for statistical methodology. In this work, we propose a robust hybrid approach referred
as Augmented Multistage Outcome-Weighted Learning (AMOL) to integrate outcome-
weighted learning and Q-learning to identify optimal DTRs from the Sequential Multiple
Assignment Randomization Trials (SMARTs). We generalize outcome weighted learning
(O-learning; Zhao et al. 2012) to allow for negative outcomes; we propose methods to re-
duce variability of weights in O-learning to achieve numeric stability and higher efficiency;
finally, for multiple-stage SMART studies, we introduce doubly robust augmentation to
machine learning based O-learning to improve efficiency by drawing information from
regression model-based Q-learning at each stage. The proposed AMOL remains valid
even if the Q-learning model is misspecified. We establish the theoretical properties of
AMOL, including the consistency of the estimated rules and the rates of convergence to
the optimal value function. The comparative advantage of AMOL over existing methods
is demonstrated in extensive simulation studies and applications to two SMART data
sets: a two-stage trial for attention deficit and hyperactive disorder (ADHD) and the
STAR*D trial for major depressive disorder (MDD).
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1 Introduction
Advances in technology in data collection is revolutionizing medical research by providing
personal data (e.g., clinical assessments, genomic data, electronic health records) for physicians
and clinical researchers to meet the promise of individualized treatment and health care.
Proliferation of these data provides new opportunities to deeply tailor treatment for each
subject while at the same time posing new challenges for statistical methodology. The goal
of this work is to develop new and powerful methods to discover optimal dynamic treatment
regimes (DTRs, Lavori and Dawson (2000)) for personalized medicine in this era of abundant
data.
The complexity, patient heterogeneity and chronicity of many diseases and disorders call for
designing treatment regimes that can dynamically adapt to an individual’s response over time
and improve long term clinical benefits. Sequential treatments, a sequence of interventions in
which the treatment decisions adapt to the time-varying clinical status of a patient, are useful
in treating many complex chronic disorders such as substance dependence, attention deficit
hyperactivity disorder (ADHD), autism spectrum disorder (ASD), major depressive disorder
(MDD), and schizophrenia (Schneider et al., 2003; Rush et al., 2004, 2006; Oslin, 2005; Jones,
2010). DTRs operationalize this process of medical decision-making and can be used to inform
clinical practice. DTRs are sequential decision rules, tailored at each stage by time-varying
patient features and intermediate outcomes in the previous stages. They are also known
as adaptive treatment strategies (Lavori & Dawson, 2000), multi-stage treatment strategies
(Thall, Sung, & Estey, 2002; Thall & Wathen, 2005) and treatment policies (Lunceford,
Davidian, & Tsiatis, 2002; Wahed & Tsiatis, 2004, 2006).
Sequential Multiple Assignment Randomized Trials (SMARTs) were proposed (Murphy,
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2005) to best construct DTRs that offer causal interpretation through randomization at each
critical decision point. Methods to identify optimal DTRs from SMARTs data have recently re-
ceived attention in the statistical community (Lavori & Dawson, 2004; Murphy, 2003; Robins,
2004; Moodie, Richardson, & Stephens, 2007; Zhang, Tsiatis, Laber, & Davidian, 2012, 2013;
Zhao, Kosorok, & Zeng, 2009; Zhao, Zeng, Rush, & Kosorok, 2012; ?, ?). See Chakraborty and
Moodie (2013) for a detailed review of the current literature. Parametric methods based on G-
computation and Monte Carlo simulation (Lavori & Dawson, 2004) and Bayesian approaches
(Wathen & Thall, 2008; Arjas & Andreev, 2000; Arjas & Saarela, 2010) were proposed. These
methods are subject to model misspecification and computationally intensive to implement,
especially in the presence of high dimensional tailoring variables. Instead of modeling the
full data generation scheme, semi-parametric methods have been developed to focus on the
contrast of conditional mean outcomes. They include methods using the “regret function”,
the expected difference in the outcomes that would have been observed if patients had taken
the optimal treatment in the current stage Murphy (2003), which is also a special case of G-
estimation proposed by (Robins, 2004; Moodie et al., 2007). Some other approaches include
regret regression methods (Almirall, Ten Have, & Murphy, 2010), marginal structural models
and structural nested mean models (Chakraborty & Moodie, 2013). Zhang et al. (2012) and
Zhang et al. (2013) developed a method based on augmented inverse probability weighting for
a single or multiple stage model. However, all these methods are based on either parametric
or semiparametric models which may lose prediction accuracy in the presence of model mis-
specification and a large number of tailoring variables, especially for small or moderate sample
sizes in real trials.
Machine learning methods originating from computer science literature have also been
recently introduced to identify optimal treatment regimes using data collected in SMARTs.
These methods are particularly suitable for dealing with a large number of subject-specific
variables. For example, Q-learning first proposed in Watkins (1989) was implemented to
analyze SMART data by Murphy, Oslin, Rush, and Zhu (2006); Zhao et al. (2009). It is a
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regression-based method to identify the optimal multi-stage decision rules, where the optimal
treatment at each stage is discovered by a backward induction to maximize the estimated Q-
function (“Q” stands for “quality of action”). The regression based Q-learning can suffer from
incorrect model assumptions. The approach selects the optimal treatment by modeling the Q-
function and its contrasts which are not explicitly related to the optimization of the objective
function. The mismatch between maximizing the Q-function and the value function potentially
leads to incorrect regimes due to overfitting the regression model. To remedy these limitations,
Zhao et al. (2012) proposed an outcome weighted learning (O-learning) which chooses the
treatment rules by directly optimizing the expected clinical outcome for single stage trials.
The resulting optimal treatment regimen can take any unconstrained functional form. Their
simulation studies demonstrate that O-learning outperforms Q-learning especially in small
sample size settings with a large number of tailoring variables. More recently, Zhao, Zeng,
Laber, and Kosorok (2014) generalized the O-learning to deal with multiple stage problem by
a backward iterative method. A direct comparison with Zhang et al. (2013) was performed
in Zhao et al. (2014) to demonstrate greater value function achieved by O-learning based
methods.
In this paper, we propose a hybrid approach to integrate O-learning and regression models
such as Q-learning, namely, Augmented Multi-stage Outcome-weighted Learning (AMOL), to
identify the optimal DTRs from SMARTs. We introduce doubly robust augmentation to ma-
chine learning based O-learning to improve efficiency by drawing information from regression
model-based Q-learning at each stage. Thus we take advantage of the robustness from the
former and the imputation ability of the latter. Compared to Zhao et al. (2012) and Zhao
et al. (2014), there are three new contributions in this work. First, for single-stage trials,
AMOL generalizes the original O-learning in Zhao et al. (2012) to allow for negative outcome
values instead of adding an arbitrarily large constant as in Zhao et al. (2012) which may lead
to numeric instability. This feature is practically appealing when there are both positive and
negative outcomes observed in a clinical study (e.g., rate of change of clinical symptoms). Sec-
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ondly, by using residuals from a regression on variables other than the treatment assignment
as outcome values, AMOL is able to reduce the variability of weights in O-learning to achieve
numeric stability and efficiency gain. Thirdly, and most importantly, for multiple-stage trials,
AMOL estimates optimal DTRs via a backward induction procedure that makes non-trivial
extension of Zhao et al. (2014) to boost efficiency through augmentation and integration with
Q-learning.
Specifically, at each stage, AMOL uses robustly weighted O-learning for estimating the
optimal DTRs, where the weights are based on the observed outcomes and conditional expec-
tations for subjects who follow the optimal treatment rules in future stages, while for those who
do not follow optimal rules in future stages, the weights are imputed from regression mod-
els obtained in Q-learning. Therefore, AMOL, as a hybrid approach, simultaneously takes
advantage of the robustness of nonparametric O-learning and makes use of the model-based
Q-learning utilizing data from all subjects. Moreover, AMOL still yields the correct optimal
DTRs even if the regression models assumed in the Q-learning are incorrect, thus maintaining
the robustness of O-learning. Similar to the double robust framework in missing data litera-
ture, AMOL aims to strike a balance between robustness and efficiency under doubly robust
estimation. However, important distinctions between the current work and the existing doubly
robust estimators include the dynamic feature of the problem and the objective function used
to maximize clinical benefits.
The rest of this paper is organized as follows. In Section 2, we review some concepts for
DTR, Q-learning and O-learning, and introduce AMOL through doubly robust augmentation.
Section 3 presents theoretical results to justify the optimality of AMOL. Section 4 shows the
results of extensive simulation studies to examine the performance of AMOL compared to
Q-learning and O-learning. In Section 5, we present data analysis results based on SMART
data for an ADHD trial (Pelham Jr & Fabiano, 2008). We present another real data example
on the STAR*D trial (Rush et al., 2004) for MDD in the Online Supplement. Lastly, we
conclude with a few remarks in Section 6.
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2 Methodologies
2.1 Dynamic Treatment Regimes (DTRs) and O-Learning
We start by introducing notation for a K-stage DTR. For k = 1, 2, . . . , K, denote Xk as the
observed subject-specific tailoring variables collected just prior to the treatment assignment
at stage k. Denote Ak as the treatment assignment taking values {−1, 1}, and denote as
Rk the clinical outcome (also known as the “reward”) post the kth stage treatment. Larger
rewards may correspond to better functioning or fewer symptoms depending on the clinical
settings. A DTR is a sequence of decision functions, D = (D1,D2, . . . ,DK), where Dk maps
the domain of patient health history information Hk = (X1, A1, . . . , Ak−1, Xk) to the treatment
choices in {−1, 1}. Let pik(a, h) denote the treatment assignment probability, Pr(Ak = a|Hk =
h). In a SMART design, it is the randomization probability for each treatment group at
each stage specified by design and thus known to the investigator. Our goal is to maximize
the total reward from all stages, i.e.,
∑K
k=1Rk. To evaluate the causal effect of a DTR,
potential outcome framework in causal inference literature is used. The potential outcome in
our context is defined as the outcome of a subject had he/she followed a particular treatment
regimen, possibly different from the observed regimen. Several assumptions are required to
infer causal effects of a DTR using data from a SMART, including the standard stable unit
treatment value assumption and the no unmeasured confounders assumption (Murphy, Van
Der Laan, & Robins, 2001; Moodie et al., 2007). Furthermore, we need the following positivity
assumption: for k = 1, ..., K and any ak ∈ {−1, 1} and hk in the support of Hk, pik(ak, hk) =
P (Ak = ak|Hk = hk) ∈ (c0, c1), where 0 < c0 < c1 < 1 are two constants. Note that
the no unmeasured confounders assumption is satisfied for SMART studies due to the virtue
of sequential randomization, while the positivity assumption requires that each DTR has a
positive chance of being observed.
Let P denote the probability measure generated by (X1, A1, R1, . . . , XK , AK , RK). Let PD
denote the conditional probability measure generated by random variables (X1, A1, R1, . . . ,
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XK , AK , RK) given that regimen D is used to assign treatment, i.e., Ak = Dk(Hk). Denote
ED as the conditional expectation with respect to the distribution PD. The value function
associated with D is defined as the expected reward given that the treatment assignments
follow regimen D (Qian & Murphy, 2011), that is, V(D) = ED
[∑K
k=1Rk
]
=
∫ ∑K
k=1Rk dPD.
Under the positivity assumption, it is easy to show that PD is dominated by P and
V(D) = E

∏K
k=1 I(Ak = Dk(Hk))(
K∑
k=1
Rk)
K∏
k=1
pik(Ak, Hk)
 . (1)
Hence, the goal is to find the optimal treatment rule D∗ that maximizes the value function,
that is, D∗ = argmaxDV(D). Without confusion, sometimes we write V(D) = V(f1, ..., fK) if
Dk is given as the sign of fk.
Recently, O-learning (Zhao et al., 2012; 2014) is proposed to estimate the optimal treatment
regimes. Specifically, for a single stage study, O-learning reformulates the value optimization
problem as a weighted classification problem where the weights are the observed rewards, and
a weighted support vector machine was proposed to estimate the optimal treatment decision
(Zhao et al., 2012). Based on n observations (Hi, Ai, Ri) with randomization probability
pii = pi(Ai, Hi), O-learning minimizes a surrogate hinge loss with L2-regularization:
min
f
n−1
n∑
i=1
(1− Aif(Hi))+Ri
pii
+ λn‖f‖2. (2)
Here, f(·) is a parametric or nonparametric decision function, ‖f‖ denotes some norm or
semi-norm of f such as the norm in a reproducing kernel Hilbert space (RKHS), and the
corresponding treatment rule is D(Hi) = sign(f(Hi)). For a multiple-stage study, Zhao et
al. (2014) proposed a backward induction to implement O-learning where at stage k, they
only used the subjects who followed the estimated optimal treatment regimes after stage k in
7
the optimization algorithm. That is, the optimal rule Dk(Hk) = sign(fk(Hk)) solves
min
f
n−1
n∑
i=1
(1− Aikfk(Hik))+Rik + · · ·+RiK
piik
I(Ai,k+1 = D̂k+1(Hi,k+1), · · · , AiK = D̂K(HiK))∏
j>k piij
+λn‖fk‖2,
where (Aik, Hik, Rik) denotes the observation at stage k, piij = pij(Aij, Hij), and D̂j is the
estimated optimal rule at stage j from the backward learning. However, as discussed before,
only using the subjects who followed the optimal regimes in future stages may result in much
information loss when K is not small. Furthermore, their method suggests to subtract a
constant from Rik’s to ensure a positive weight in the algorithm, where the choice of constant
may be arbitrary.
2.2 General Framework to Improve O-Learning
In this section, we describe theoretical motivation and general ideas to improve O-learning.
First consider a single-stage trial with data (Ai, Hi, Ri), i = 1, ..., n. Detailed implementation
of the improved O-learning for a multiple-stage study will be given in the next section.
The key idea to improve O-learnings is to replace weights Ri in (2) by surrogate weights
R˜i so that under certain regularity conditions, we achieve two desirable properties: (a) the
treatment rule minimizing
min
f
n−1
n∑
i=1
(1− Aif(Hi))+ R˜i
pii
+ λn‖f‖2 (3)
is still asymptotically consistent; and (b) the derived rule has smaller variability compared
to using Ri as weights. Property (a) ensures that using new weights R˜i still yields a correct
optimal treatment regime, while property (b) implies that the new rule is estimated more
accurately than the one given by O-learning. To achieve these goals, first observe that as
shown in Zhao et al. (2012), the optimal rule minimizing (3), assuming that λn vanishes
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asymptotically, has the same sign as E[R˜|A = 1, H] − E[R˜|A = −1, H]. Therefore, property
(a) is asymptotically equivalent to requiring
sign {E[R|A = 1, H]− E[R|A = −1, H]} = sign
{
E[R˜|A = 1, H]− E[R˜|A = −1, H]
}
. (4)
For (b), to examine accuracy of the estimated rule, we assume f(h) to be a parametric function
θTφ(h) where φ(h) is a vector of some pre-defined basis functions. Thus, under the same
regularity conditions in (Koo, Lee, Kim, & Park, 2008) and following their proofs, we can
show that the asymptotic variance of the estimator for θ is
E
[
R˜δ(1− Af ∗(H))φ(H)φ(H)T/pi(A,H)
]−1
E
[
R˜2I(1− Af ∗(H) > 0)φ(H)φ(H)T/pi(A,H)2
]
×E
[
R˜δ(1− Af ∗(H))φ(H)φ(H)T/pi(A,H)
]−1
, (5)
where δ(·) denotes the Dirac function and f ∗ is the unique minimizer for E[R˜(1−Af(H))+].
Consequently, from (4) and (5), we conclude that if R˜ satisfies
E[R˜|A,H] = E[R|A,H], V ar(R˜|A,H) ≤ V ar(R|A,H),
then since
E
[
R˜δ(1− Af ∗(H))φ(H)φ(H)T
]
= E
[
Rδ(1− Af ∗(H))φ(H)φ(H)T ] ,
but
E
[
R˜2I(1− Af ∗(H) > 0)φ(H)φ(H)T
]
≤ E [R2I(1− Af ∗(H) > 0)φ(H)φ(H)T ] ,
using the new weights R˜i should yield a more accurate estimated and consistent rule in a large
sample sense. As a remark, the above conclusion is independent of the choice of large margin
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loss functions. In other words, if we replace the hinge loss (1 − Af(H))+ by other types of
large margin losses, using the new weights R˜i still leads to a more efficient estimation of the
optimal treatment rule.
Note that O-learning in (3) is invariant to rescaling R˜i by any positive constant. Thus,
we can always assume |R˜i| ≤ 1 after a proper scaling. We further observe from (4) that the
derived rule remains consistent if we replace R˜i by R˜i − s(Hi) for any measurable function
s(H). Particularly, if we choose a good candidate s(H) so that the upper bound of |R− s(H)|
is even smaller than |R| conditional on H with a large probability, then the value loss due to
finite sample estimation may be reduced. One heuristic justification for the latter is based on
the proof of Theorem 3.4 in Zhao et al. (2012), also seen in Steinwart & Scoverl (2007), where it
shows that the upper bound for the value loss due to the derived rule is a monotone function of
a constant CL which is the Lipschitz constant of the weighted loss function, wi(1−Aif(Hi))+
with respect to f in L2(P )-norm. Thus, if E[(R˜i − s(Hi))2|Hi] is less than E[R˜2i |Hi], this
bound under the weight wi = (R˜i − s(Hi)) is tighter than the one under the weight wi = R˜i.
In particular, we can choose s(Hi) to be an approximation to E[R˜i|Hi] and then use R˜i−s(Hi)
as the new weights in (3). In other words, we propose to minimize
min
f
n−1
n∑
i=1
(1− Aif(Hi))+ R˜i − s(Hi)
pii
+ λn‖f‖2. (6)
Our subsequent simulation studies show that this modification can sometimes significantly
improve the original O-learning.
Finally, by using the new weights R˜i − s(Hi), the weights in (6) will have negative val-
ues which renders the objective function in (6) to be non-convex. To fix this issue, since
asymptotically the goal of optimization is to derive a rule minimizing
E
[
R˜− s(H)
pi(A,H)
I(A 6= sign(f(H)))
]
,
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which is equivalent to
E
[
|R˜− s(H)|
pi(A,H)
I(Asign(R˜− s(H)) 6= sign(f(H)))
]
− E
(
(R˜− s(H))−
pi(A,H)
)
,
this suggests that we can minimize
min
f
n−1
n∑
i=1
(1− Aisign(R˜i − s(Hi))f(Hi))+ |R˜i − s(Hi)|
pii
+ λn‖f‖2, (7)
which is a convex optimization problem. Intuitively, for a subject with large positive outcome
R˜i − s(Hi), the desirable decision rule is to choose the currently observed treatment Ai since
f(Hi) is encouraged to have the same sign as Ai. In contrast, for a subject with negative
outcome R˜i − s(Hi), the currently observed A′is might not be the best treatment choice, so a
desirable decision rule is encouraged to be the alternative treatment −Ai.
In summary, we propose the following steps to improve the single stage O-learning:
Step 1. Identify new weights R˜i which have the same conditional mean as Ri but smaller
variance, and estimate them consistently as R̂i = ĝ(Ri, Ai, Hi) with some data-dependent
function ĝ(·);
Step 2. Find a function ŝ(Hi) to approximate E[R˜i|Hi], for instance, through a regression
model of R̂i on Hi, and calculate the new weight R̂i − ŝ(Hi);
Step 3. Solve the minimization problem in (7) to estimate f(H), where R˜i− s(Hi) is replaced
by R̂i − ŝ(Hi).
Computationally, minimizing (7) can be carried out using an algorithm similar to support
vector machine. Specifically, it is equivalent to solving a convex optimization with slack
variables ξ′is:
min
f,ξi
1
2
‖f‖2 + C
n∑
i=1
ξi
|R̂i − ŝ(Hi)|
pii
subject to ξi ≥ 0, sign(R̂i − ŝ(Hi))Aif(Hi) ≥ 1− ξi,∀i = 1, ..., n.
(8)
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The decision function f(h) could be linear f(h) = hTβ + β0, or a linear combination of basis
functions of a functional space H: f(h) = φ(h)T θ + θ0, where φ(h) = (φ1(h), . . . , φm(h), . . . ),
and φ can have finite or infinite dimensions. In both cases, we solve for parameters θ and θ0
via the dual problem:
max
α′is
n∑
i=1
αi − 1
2
n∑
i=1
n∑
j=1
αisign(R̂i − ŝ(Hi))AiK(Hi, Hj)Ajsign(R̂i − ŝ(Hi))αj
subject to 0 ≤ αi ≤ C|R̂i − ŝ(Hi)|/pii, where K(·, ·) is a kernel function. The coefficient θ is
computed as
θ̂ =
n∑
i=1
αisign(R̂i − ŝ(Hi))Aiφ(Hi)
and the intercept parameter θ0 can be computed from the Karush-Kuhn-Tucker (KKT) con-
ditions. Finally, kernel tricks can be used to estimate nonlinear function f(h) when K(·, ·) is
chosen to be some nonlinear kernel such as the Gaussian kernel.
2.3 Simple Augmented Multistage O-Learning (AMOL)
Here we apply the general idea of improving O-learning to multiple-stage studies. Since DTRs
aim to maximize the expected cumulative rewards across all stages, the optimal treatment
decision at the current stage must depend on subsequent decision rules and future clinical
outcomes or rewards under those rules. This observation motivates us to use a backward
recursive procedure similar to the backward induction in Q-learning and O-learning in Zhao
et al. (2014). At each stage, we will follow Steps 1-3 as given in the previous section with
carefully chosen weights. Specifically, the new weights in Step 1 is based on imputing the
outcomes for subjects who do not follow the estimated optimal rule in latter stages through a
regression model so as to use information from all the subjects at all stages. The imputation
is realized in a manner similar to the augmented inverse probability weighted complete-case
(AIPWCC) method in the missing data literature (Tsiatis, 2006), where we robustly estimate
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the optimal treatment regimes even if the regression imputation model is misspecified.
The proposed augmented multistage outcome-weighted learning (AMOL) is described as
follows. Start from the last stage K. Following the proposed improved single-stage O-learning,
we first fit a parametric regression model to estimate E[RiK |HiK ] as ŝK(HiK), and then solve
f̂K = argminfKn
−1
n∑
i=1
(1− sign(RiK − ŝK(HiK))AiKfK(HiK))+|RiK − ŝK(HiK)|
piiK(AiK , HiK)
+λnK‖fK‖2.
Denote the optimal decision at the last stage as D̂K(h) = sign(f̂K(h)).
To identify the optimal treatment rule for stage K− 1, we need to determine the potential
future reward had the subject followed the optimal treatment at stage K. Clearly, for subject
i whose assigned treatment AiK is the same as the optimal treatment, D̂K(HiK), the optimal
reward value is the observed RiK since the observed treatment assignment at the last stage
is optimal. For subjects who did not receive the optimal treatment D̂K(HiK), the observed
RiK is no longer the maximal reward following the optimal treatment rule. However, using
all subjects and their health history information at this stage, one can fit a regression model
for RiK given (AiK , HiK). This model can be either parametric or fully nonparametric. From
this estimated regression model, the optimal reward expected at the last stage given history
information HK = h can be obtained if the regression model is correctly specified. That is,
we can obtain the expected maximal reward at stage K as
ĝK(HK) = max
a∈{−1,1}
Ê[RK |AK = a,HK = h], (9)
where Ê[·] denotes the predicted mean from fitting a regression model of Rk given Ak and Hk
(including their interactions).
The estimated optimal reward ĝK(HK) for a subject in (9) is only valid under the as-
sumption that the regression model used to estimate the conditional mean in (9) is correctly
specified. Therefore, in order to simultaneously use all the subjects and be protected from
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misspecification of the regression model, we construct pseudo-outcomes for doubly robust es-
timation using a similar strategy as in the missing data literature. Considering subjects who
did not follow the optimal treatment assignment at stage K as missing outcomes, we form
pseudo-outcomes
Q̂iK =
I(AiK = D̂K(HiK))
piK(AiK , HiK)
RiK − I(AiK = D̂K(HiK))− piK(AiK , HiK)
piK(AiK , HiK)
ĝK(HK). (10)
The first term in Q̂iK is the inverse probability weighted complete-case estimator since only
when I(AiK = D̂K(HiK)) = 1 would the observed outcome RiK be deemed as non-missing.
The second term is an augmentation term incorporating contributions from the subjects who
did not receive the optimal treatment assignments. For these subjects, their pseudo-outcomes
reduce to the conditional expectations ĝK(HK). We take Ri,K−1 + Q̂iK as the outcome R˜ik
in a single-stage O-learning and follow Steps 2-3 in the improved O-learning. Denoting the
weights for stage K − 1 as
Ŵi,K−1 =
Ri,K−1 + Q̂iK − ŝK−1(Hi,K−1)
pii,K−1(Ai,K−1, Hi,K−1)
,
where ŝK−1(Hi,K−1) is the estimated mean of Ri,K−1 + Q̂iK given Hi,K−1 based on a regression
model, we can estimate the optimal rule for stage K − 1 by minimizing
n−1
n∑
i=1
(1− sign(Ŵi,K−1)Ai,K−1fK−1(Hi,K−1))+|Ŵi,K−1|+ λn,K−1‖fK−1‖2. (11)
The optimal rule at stage K − 1 is then D̂K−1(h) = sign(f̂K−1(h)).
The above procedure can be continued to other stages. Specifically, at the (k− 1)th-stage,
we first regress Rk + ĝk+1(Hk+1) on Ak, Hk and their interactions to compute
ĝk(h) = max
a∈{−1,1}
Ê[Rk + ĝk+1(Hk+1)|Ak = a,Hk = h],
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where Ê[·] is the predicted mean from the regression model ofRk+ĝk+1(Hk+1) on (Ak, Hk, AkHk).
Second, we compute the pseudo-outcomes
Q̂ik =
∏K
j=k I(Aij = D̂j(Hij)(
∑K
j=k Rij)∏K
j=k pij(Aij, Hij)
−
∏K
j=k I(Aij = D̂j(Hij))−
∏
j≥k pij(Aij, Hij)∏
j≥k pij(Aij, Hij)
ĝk(Hi,k).
Following Steps 2-3 in the improved O-learning, we denote the weight for stage k−1 as Ŵi,k−1,
where
Ŵi,k−1 =
Ri,k−1 + Q̂ik − ŝk−1(Hi,k−1)
pik−1(Ai,k−1, Hi,k−1)
with ŝk−1(Hi,k−1) being the estimated mean of (Ri,k−1 + Q̂ik) given Hi,k−1. Then we estimate
the optimal rule for stage k − 1 by computing the minimizer, f̂k−1, of the following function:
n−1
n∑
i=1
(
1− sign(Ŵi,k−1)Ai,k−1fk−1(Hi,k−1)
)+ ∣∣∣Ŵi,k−1∣∣∣+ λn,k−1‖fk−1‖2. (12)
The corresponding optimal rule at stage k − 1 is D̂k−1(h) = sign(f̂k−1(h)). We repeat this
procedure for all K stages.
When the regression imputation model is correct, we expect AMOL to improve estimation
efficiency by borrowing information from the model-based Q-learning. However, when the
imputation model is misspecified, AMOL continues to provide consistent decision functions
due to the double robustness (see Theorem 3.3), while Q-learning does not maintain this
consistency. This is due to using the augmented inverse probability weighted complete-case
estimator. Therefore as long as either the piik or the conditional expected outcome ĝi,k is
estimated consistently, Ri,k−1 +Qik is a consistent estimator of the reward under the optimal
regimen in future stages. For SMART studies, the randomization probabilities are known by
design. Thus, pi′iks are always correctly specified, and the double robustness ensures consistency
of AMOL.
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2.4 Improve Efficiency of AMOL
The augmentation (10) in the previous section, although easy to be implemented, may not
be the best augmentation for all stages in the context of missing data. This is because at
stage k, it does not account for the heterogeneity in the observed treatment patterns (i.e.,
“missing data patterns”, or patterns of whether an optimal treatment is received at a future
stage) among all subjects who do not take optimal treatments in any future stage. In other
words, subjects who “missed” one stage of optimal treatment in the future stage is weighted
the same as subjects who “missed” more than one stage of optimal treatment. Specifically,
for any subject i with observed history information Hik, the simple AMOL augmentation
estimates the value increment since stage k under the optimal treatment rules, denoted by
Qik = R
(D∗)
ik +...+R
(D∗)
iK , where V
(D∗)
ik is the potential value for any variable Vik if the treatment
rules are optimal from stage k onwards, i.e., Aij = D∗j (Hij), for all j = k, k + 1, ..., K, only
using information up to stage k (i.e., Hik) regardless of the heterogeneity in future stages after
stage k (some stages optimal and some stages non-optimal).
We propose a more efficient AMOL taking into account the additional information in
observed treatment patterns since stage k. Specifically, for j ≥ k, let Mi,k−1 = 0 and let
Mij = I(Aik = D∗k(Hik), ..., Aij = D∗j (Hij)) denote whether subject i follows the optimal
treatment regimes from stage k to j. Let Cij = Mi,j−1−Mij indicate that subject i follows the
optimal treatment up to stage j−1 but does not in stage j. Corresponding to the optimal rule
(D∗k, ...,D∗K), the complete data for subject i would be (Hik, H(D∗)iK , R(D∗)iK ), where H(D∗)iK includes
all the potential interim outcomes and health history information up to the last stage K if
the optimal treatment rule (D∗k, ...,D∗K) were implemented from k to K. The observed data
follow a monotone missing pattern: for subject i with Cij = 1, we only observe (Hik, H
(D∗)
ij )
with H
(D∗)
ij being a subset of H
(D∗)
iK (since for this subject only treatments from stage k to j
are optimal); and only subjects with MiK = 1 have observed complete data. From the theory
of Robins (1994), also seen in Tsiatis (2006) and Zhang et al. (2013), the optimal estimation
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of Qik under the monotone missingness and coarsening at random assumption is to use the
following augmentation:
Qik =
MiK(Rik + ...+RiK)
P (MiK = 1|HiK) +
K∑
j=k
Cij − P (Cij = 1|Mi,j−1 = 1, Hij)Mi,j−1
P (Mij = 1|Hij) mkj(Hij),
where mkj(Hij) = E[Qik|H(D∗)ij = Hij]. From the sequential randomization, we know
P (Mij = 1|Hij) =
j∏
s=k
pis(D∗s(His), His)
and
P (Cij = 1|Mi,j−1 = 1, Hij) = 1− pij(D∗j (Hij), Hij).
Finally, from the sequential randomization and sequential consistency assumption for potential
outcomes, we obtain
mkj(Hij) = E[Qik|H(D∗)ij = h]
= E[R
(D∗)
ik + ...+R
(D∗)
i,j−1 +Qij|H(D∗)ij = h,Aik = D∗k(Hik), ...Ai,j−1 = D∗j−1(Hi,j−1)]
= E[Rik + ...+Ri,j−1 +Qij|Hij = h,Aik = D∗k(Hik), ...Ai,j−1 = D∗j−1(Hi,j−1)]
= Rik + ...+Ri,j−1 + E[Qij|Hij = h,Aik = D∗k(Hik), ...Ai,j−1 = D∗j−1(Hi,j−1)],
which can be estimated using ĝj(h) +Ri,j−1 + ...+Rik for subjects with Mi,j−1 = 1 as defined
in Section 2.2.
To implement the more efficient AMOL, at stage k − 1, assuming that we have already
obtained the optimal rules after this stage, denoted by D̂k, ..., D̂K , define
M̂ij = I(Aik = D̂k(Hik), ..., Aij = D̂j(Hij)),
and define Ĉij similarly. We estimate P (Mij = 1|Hij) by P̂ (Mij = 1|Hij) =
∏j
s=k pis(D̂s(His), His)
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and estimate P (Cij = 1|Mi,j−1 = 1, Hij) by P̂ (Cij = 1|Mi,j−1 = 1, Hij) = 1−pij(D̂j(Hij), Hij).
Then the pseudo-outcome for Qik is calculated as
Q̂ik =
M̂iK(Rik + ...+RiK)
P̂ (MiK = 1|HiK)
+
K∑
j=k
Ĉij − P̂ (Cij = 1|Mi,j−1 = 1, Hij)M̂i,j−1
P̂ (Mij = 1|Hij)
×{ĝj(Hij) +Ri,j−1 + ...+Rik} . (13)
Once Q̂ik is obtained, the algorithm to estimate more efficient AMOL proceeds exactly the
same as Section 2.3.
As a remark, no matter how mkj(Hij) is estimated, the double robustness of the above aug-
mentation ensures the asymptotic unbiasedness of Q̂ik. Particularly, if we estimate mkj(Hij)
using ĝk(Hik), i.e., discard partially available information for each treatment pattern (or miss-
ingness pattern), then after some algebra, we see that the general AMOL algorithm presented
here reduces to the simple AMOL in Section 2.3. In other words, the simple AMOL is a par-
ticular augmentation to estimate Qik at stage k. It is equivalent to the more efficient AMOL
when there is no intermediate information collected, i.e., Hij = Hik (note that the treatment
assignment is determined by Hik under the optimal rule).
3 Theoretical Results
We first establish the theoretical results for single-stage AMOL (K = 1) where the weights
are obtained following Steps 1-3 in Section 2.3. Our first theorem provides the risk bound
for V(f̂), where f̂ minimizes (7) with R˜ = ĝ(R,A,H) for a data-dependent function ĝ(·) and
s(H) = ŝ(H) for some estimated function ŝ(·). We assume that
η∗(x) =
E[R|A = 1, X = x]− E[R|A = −1, X = x]
E[R|A = 1, X = x]/pi(1, x) + E[R|A = −1, X = x]/pi(−1, x) +
1
2
satisfies the following geometric noise exponent condition (c.f., Steinwart and Scovel, 2007):
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Definition 3.1 (Geometric noise exponent condition (q, p)). For a given function η(x), we
define
O+ = {x ∈ Supp(X) : 2η(x)− 1 > 0} , O− = {x ∈ Supp(X) : 2η(x)− 1 < 0} .
Let ∆(x) = d(x,O+) if x ∈ O−, ∆(x) = d(x,O−) if x ∈ O+, where d(x,O) is the distance of
x from a set O. Then η(x) ∈ (0, 1) is assumed to satisfy condition GNE(q) if there exists a
constant C > 0 such that for any θ > 0,
E
[
exp(−∆(X)
2
θ
)|2η(X)− 1|
]
≤ Cθqp/2,
where p is the dimension of X.
As explained in Zhao et al. (2012), this geometric noise exponent condition describes the
distribution behavior in a neighborhood of the optimal treatment rule. In the situation that
optimal treatment assignment is distinct, i.e., |2η∗(x)− 1| > δ for some positive constant δ, q
can be any large number.
Theorem 3.2. Suppose that the RKHS is the Gaussian kernel space with bandwidth σn. Under
the GNE(q) condition, assume that σn = λ
−1/(q+1)p
n , λn → 0 and nλn →∞. Additionally, we
assume that there exist some function g∗(R,A,H) and s∗(H) with finite second moments such
that E[g∗(R,A,H)|A,H] = E[R|A,H],
P
{
E[|ĝ(R,A,H)− g∗(R,A,H)|+ |ŝ(H)− s∗(H)|] ≤ c′τ/nβ} > 1− e−τ
and P
{‖ĝ‖∞ + ‖ŝ‖∞ ≤ c′τ/√λn} > 1− e−τ for some constants c′ and β > 0 . Then for any
δ > 0, 0 < v ≤ 2, there exists a constant c such that for all τ ≥ 1,
P
{
V(f̂) ≥ V(f ∗)− n(τ)
}
≥ 1− e−τ ,
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where
n(τ) = c
[
n−β + λ
− 2
2+v
+
(2−v)(1+δ)
(2+v)(1+q)
n n
− 2
2+v +
τ
nλn
+ λ
q
q+1
n
]
.
This theorem implies that V(f̂)→ V(f ∗) in probability and, moreover,
V(f̂)− V(f ∗) = Op
(
n−β + λ
− 2
2+v
+
(2−v)(1+δ)
(2+v)(1+q)
n n
− 2
2+v +
1
nλn
+ λ
q
q+1
n
)
.
The proof of Theorem 3.2 follows from a similar argument to (Zhao et al., 2012).
Next, we establish the properties for the simple AMOL in Section 2.3. Our first result is
to justify the use of augmentation in AMOL by the following theorem whose proof is given in
the appendix.
Theorem 3.3. For any function µ(h) which maps from the history information Hk to the
outcome domain,
Rk−1 +
∏K
j=k I(Aj = D∗j (Hj)(
∑K
j=k Rj)∏K
j=k pij(Aj, Hj)
−
∏K
j=k I(Aj = D∗j (Hj))−
∏
j≥k pij(Aj, Hj)∏
j≥k pij(Aj, Hj)
µ(Hk)
is always unbiased for E[Rk−1 + Qk|Hk], and its conditional variance given Hk is minimized
if and only if
µ(Hk) = E[Qk|Hk] +
{
V ar(
I(
∏K
j=k I(Aj = D∗j (Hj))∏K
j=k pij(Aj, Hj)
|Hk)
}−1
×E
[
I(
∏K
j=k I(Aj = D∗j (Hj))∏K
j=k pij(Aj, Hj)
1−∏Kj=k pij(Aj, Hj)∏K
j=k pij(Aj, Hj)
(Qk − E[Qk|Hk])|Hk
]
.
Here, Qk =
∑
j≥k Rj under the optimal decision rule, Aj = D∗j (Hj), j ≥ k. Particularly, when
pij(Aj, Hj) is constant for all j = 1, ..., K, the optimal µ(Hk) is E[Qk|Hk].
Theorem 3.3 proves that using augmentation, the simple AMOL enjoys a desirable property
in that it always yields the correct future outcome and value function associated with decision
rule D, even if the regression model from the Q-learning for imputation is misspecified. Thus,
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AMOL is expected to yield the correct optimal DTRs even under misspecification. Moreover,
if the regression model is correctly specified, then the proposed AMOL can have the smallest
variability among all unbiased augmentations. Consequently, the identified DTR is also least
variable.
Our last theorem gives the value loss due to the estimated DTRs in the simple AMOL.
Recall a treatment decision rule for the multi-stage DTR is determined by a sequence of
functions f = (f1, f2, ..., fK) which maps from (H1, ..., HK) to {−1, 1}K . The value function
associated with this treatment decision rule is defined as
V(f1, ..., fK) = E
[
(
∑K
j=1Rj)Π
K
j=1I(Aj = sign{fj(Hj))}
ΠKj=1pij(Hj, Aj)
]
.
Further, define the value function at the kth-stage as
Vk(fk, ..., fK) = E
[
(
∑K
j=k Rj)Π
K
j=kI(Aj = sign{fj(Hj))}
ΠKj=kpij(Hj, Aj)
]
.
Then the following theorem gives the main result regarding Vk(f ∗k , ..., f ∗K)− Vk(f̂k, ..., f̂K) for
k = 1, ..., K, where (f ∗1 , ..., f
∗
K) is the theoretical optimal treatment rules as given in (Zhao et
al., 2012).
Theorem 3.4. Let η∗k be defined the same as η
∗ with the following substitution: A = Ak, X =
Hk and substitute R with the summation of Rk and the optimal rewards for all future stages.
Assume
(C.1) η∗k satisfies the GNE condition with q = qk and p = pk.
(C.2) For k = 1, ..., K − 1 and τ > 0, there exist some function g∗k(Hk+1) and s∗k(Hk) such
that
P
{
E[|ĝk(Hk+1)− g∗k(Hk+1)|+ |ŝk(Hk)− s∗k(Hk)|] ≤ c′τ/nβk
}
> 1− e−τ
and P
{‖ĝk‖∞ + ‖ŝk‖∞ ≤ c′τ/√λn,k+1} > 1− e−τ for some constants c′ and βk > 0
(C.3) The RKHS is the Gaussian kernel space with bandwidth σnk = λ
−1/(qk+1)pk
nk and λnk
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satisfies nλnk →∞.
Then it holds that for any δk > 0, 0 < vk ≤ 2, there exists a constant c such that for all τ ≥ 1,
P
{
Vk(f̂k, ..., f̂K) ≥ Vk(f ∗k , ..., f ∗K)−
K∑
j=k
c
−(K−j)
0 nj(τ)
}
≥ 1− (K − j + 1)e−τ ,
where
nk(τ) = c
[
λ
− 2
2+vk
+
(2−vk)(1+δk)
(2+vk)(1+qk)
nk n
− 2
2+vk +
τ
nλnk
+
τ
nβk
+ λ
qk
qk+1
nk
]
.
The above condition (C.1) is the standard condition in support vector machine theory and
this condition describes the data distribution near the optimal separation boundary at each
stage. Condition (C.2) is the assumed condition for the prediction model to estimate gk and
sk. This condition holds naturally for βk < 1/2 if gk and sk are from a parametric working
model. This theorem implies that Vk(f̂k, ..., f̂K)→ Vk(f ∗k , ..., f ∗K) in probability. Furthermore,
the convergence rate of this approximation depends on the separability of the optimal treat-
ment regimes, which is reflected by qk in the geometric noise exponent condition, and the
approximation of the weights in terms of βk from all stages since stage k. A proof of this
theorem is provided in the Appendix.
Finally, for the general AMOL given in Section 2.4, since the only difference from the simple
AMOL is the use of Q̂ik for k = 1, ..., K, both Theorems 3.3 and 3.4 hold. In particular, the
result of Theorem 3.3 follows from the double robustness property given in Theorem 10.4 in
Tsiatis (2008). Furthermore, their result shows that no matter what mkj(Hj) is used in the
augmentation, the obtained Qik’s estimate has smaller variability as compared to the inverse
probability weighted estimator. That is, the general AMOL should lead to more efficient
estimation of the optimal treatment rule than the O-learning. The proof for the results in
Theorem 3.4 remains the same except that the approximation of Q̂ik to Qik depends on the
approximation errors of ĝkj to its limit g
∗
kj for j ≥ k, which does not affect the risk bound as
given in Theorem 3.4.
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4 Simulation Studies
We conducted extensive simulation studies to compare simple and more efficient AMOL with
existing approaches by the value function (reward) of the estimated treatment rules. Particu-
larly, we compared four methods: (a) Q-learning based on a linear regression model with lasso
penalty; (b) O-learning as in Zhao et al. (2014); (c) AMOL1, the simple AMOL introduced
in section 2.3, where linear regression models with lasso penalty were used to estimate ŝk and
ĝk; (d) AMOL2, the more efficient AMOL introduced in section 2.4, where linear regression
models with lasso penalty were used to estimate ŝk and ĝk. Additionally, in both Q-learning
and the estimation of ĝk, the interactions between treatment and health history were included
in the regression models. Our simulation settings imitated either a two-stage or a four-stage
trial. In the following, we only report the results from the four-stage settings while we provide
the results from the two-stage designs in the Supplementary Material.
In the first four-stage setting, we considered 20 feature variables simulated from a multivari-
ate normal distribution, where the first ten variables X1, · · · , X10 had a pairwise correlation
of 0.2, the rest 10 variables were uncorrelated, and the variance for Xj’s is 1. The reward
functions were generated as follows:
R1 = X1A1 +N (0, 1); R2 = (R1 +X22 +X23 − 0.8)A2 +N (0, 1);
R3 = 2 ∗ (R2 +X4)A3 +X25 +X6 +N (0, 1); R4 = (R3 − 0.5)A4 +N (0, 1).
The randomization probabilities of treatment assignment at each stage were allowed to depend
on the feature variables through
P (A1 = 1|H1) = 1
1 + exp(−0.5X1) ; P (A2 = 1|H2) =
1
1 + exp(0.1R1)
;
P (A3 = 1|H3) = 1
1 + exp(0.2X3)
; P (A4 = 1|H4) = 1
1 + exp(0.2X4)
.
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In the second four-stage setting, we imitated a situation where the whole population consisted
of a finite number of latent subgroups for which the optimal treatment rule was the same
within the group. Specifically, we assumed that there were 10 latent groups, labeled as 1 to
10. For subject in group l, given a randomly assigned treatment sequence (A1, A2, A3, A4),
the rewards were generated from R1 = R2 = R3 = 0 and R4 =
∑4
j=1AjA
∗
jl + N(0, 1),
where A∗jl = 2(
⌊
l
2(j−1)
⌋
mod 2) − 1. Therefore, for any subject from group l, the optimal
treatment rule should be (A∗1l, ..., A
∗
4l). However, in practice, we did not observe the group
label; instead, we observed feature variables which might be informative of the latent group.
In this simulation study, the feature variables consisted of (X1, ..., X30) from a multivariate
normal distribution with the same correlation matrix as the previous setting. Furthermore,
X1, ..., X10 had the same mean value µl which was a group-specific constant generated from
N(0, 5), but the mean of X11, ..., X30 were all zeros. In other words, only X1, ..., X10 were
informative of the group label but the rest variables were pure noises.
For each data, we applied Q-learning, O-learning and our proposed methods (AMOL1
and AMOL2) to estimate the optimal rule. At each stage k, the patient’s health history
Hk contained feature variables up to stage k, treatment assignments received at all previous
stages, interaction between treatment and feature variable at each previous stages, and interim
outcomes at previous stages. Additionally, linear kernel was used for O-learning, AMOL1, and
AMOL2, and the cost parameter was selected by four-fold cross validation. For each method,
the value function corresponding to the estimated optimal rule was computed using expression
(1) from the empirical average of a large independent test data with sample size 20, 000.
The results from 500 replicates are presented in Figures 1 and 2 and Table 1. In the first
setting, we observe that Q-learning incorporating lasso variable selection has high variability
of the value function in small sample (n =50), but becomes significantly better with increasing
sample sizes (e.g., 200 and 400) since the true model for the reward function is based on a
regression model. Comparatively, AMOL1 and AMOL2 both have a significant improvement
over O-learning in all sample sizes in terms of larger value and smaller variability due to the
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Table 1: Mean and median of empirical value function for 3 simulation scenarios evaluated on
independent testing data.
Simulation setting 1 (optimal value 10.1)
n Q-learning Olearning AMOL1 AMOL2
Mean (Std) Median Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 4.672(2.154) 3.793 2.605(1.490) 2.607 5.228(1.156) 5.197 5.030(1.075) 5.038
100 6.004(2.557) 4.196 3.001(1.453) 2.959 5.704(0.952) 5.680 5.634(0.946) 5.625
200 7.774(2.135) 8.908 3.521(1.362) 3.529 6.242(0.817) 6.151 6.417(0.812) 6.406
400 8.736(1.117) 9.032 4.521(1.279) 4.568 6.685(0.664) 6.700 7.034(0.706) 7.066
Simulation setting 2 (optimal value 4)
n Q-learning Olearning AMOL1 AMOL2
Mean (Std) Median Mean (Std) Median Mean (Std) Median Mean (Std) Median
50 0.890(0.090) 0.900 0.726(0.536) 0.721 1.523(0.523) 1.504 1.502(0.510) 1.496
100 0.563(0.217) 0.473 1.027(0.431) 1.021 2.052(0.458) 2.074 2.049(0.425) 2.076
200 0.954(0.241) 0.923 1.251(0.498) 1.272 2.428(0.365) 2.443 2.451(0.388) 2.411
400 0.861(0.226) 0.855 1.639(0.446) 1.628 2.846(0.353) 2.859 2.879(0.351) 2.879
data augmentation in the propose methods. They also outperforms Q-learning in small sample
sizes (n = 50 and n = 100). Moreover, when the sample size increases, AMOL2 tends to yield
slightly larger mean and median value than AMOL1. This may be because AMOL2 makes use
of better augmentation so leads to more accurate estimate of the optimal rule. In the second
setting, since the rewards are generated from a latent mixture model, the regression model
in Q-learning is very likely to be misspecified, and thus it performs poorly under all sample
sizes (only achieves a median of 0.85 when n = 400, compared to the actual optimal value 4).
Instead, both AMOL1 and AMOL2 outperform O-learning and Q-learning in all cases, and
achieves a value median value of 2.88 for a sample size of 400. AMOL1 and AMOL2 perform
similarly in terms of mean and median values. Similar conclusion is observed in the two-stage
simulation studies reported in the Supplementary Material.
5 Application
Our first application is based on a two-stage SMART for children affected by ADHD (Pelham Jr
& Fabiano, 2008; ?, ?). Interventions in the ADHD trial were different doses of metham-
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Figure 1: Simulation setting 1 with four-stage design (optimal value=10.1)
Figure 2: Simulation setting 2 with four-stage design (optimal value=4)
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phetamine (MED) and different intensities of behavioral modification (BMOD). As shown in
Figure 3, children were randomly assigned to begin with low-intensity behavioral modification
or with low-dose medication. This stage lasted for two months, after which the Impairment
Rating Scale (IRS) and the individualized list of target behaviors (ITB) were used to assess
each child’s response to initial treatment. Children who responded continued to receive the
initial low intensity treatment, and children who did not respond were re-randomized to either
intensify the initial treatment or switch to the other type of treatment. The primary outcome
of the study was a school performance score measured at the end of study which ranges from
1 to 5. For the ADHD data, there were 150 patients in total, 51 in-remission after the first
stage, and 99 entered second stage randomization. The randomization probabilities were 0.5
at both stages.
We compared the performance of Q-learning, O-learning and AMOL when analyzing the
ADHD data, nothing that AMOL1 and AMOL2 were equivalent for a two-stage trial. The
feature variables for the first stage included ODD (Oppositional Defiant Disorder) Diagnosis,
baseline ADHD score, race (white) and prior medication prescription. There were two inter-
mediate variables, months to non-response and adherence to the first stage treatment, to be
included as the feature variables for the second stage in addition to those from the first stage.
The final reward was the school performance score at the end of second stage.
For comparison, we randomly partitioned data into a training set and a testing set with
sample size ratio 5:1. We then estimated the optimal treatment rule using each method using
the training data, and then evaluated the predicted value function in the test data. Particulary,
the empirical value function was calculated using expression (1), where Dk’s were replaced by
the estimated optimal rules.
LASSO penalization was applied in both Q-learning and the regression steps of AMOL.
Here we considered for the remissed patients, continue the current treatment is their optimal
treatment. So to learn the optimal rule for second stage all three methods used the nonre-
missed patients for second stage. Q-learning was not weighted, O-learning and AMOL were
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weighted by randomization probability pi2 = 0.5. For the first stage, Q-learning used all the
patients with no weights. All patients had their final outcome at the end of second stage. O-
learning considered the remissed and nonremissed whose observed treatment 2 was the same
as estimated optimal. The outcome for the remissed patient was the final outcome weighted by
pi1, the outcome for the non-remissed patients were weighted by pi1∗pi2; and AMOL considered
the all the patients with complete data for the first stage, the remissed patients were considered
in the group whose observed treatment were the same with optimal. AMOL pseudo-outcome
was computed and the weights were first stage randomization probability pi1 = 0.5
The box plot of the value estimates from 500 times of randomly splitting training and
testing data is presented in Figure 4. The best one-size-fits-all rules yielded a score of 3.51
points for the treatment rule beginning with BMOD and then augmenting with MED; and
the worst one-size-fits-all rule was to begin with BMOD and intensify BMOD, which yielded
a value of 2.65 points. However, AMOL achieved an average mean value of 3.82, which is
higher than both O-learning (3.04) and Q-learning (3.58). To visualize the importance of
each tailoring variable on the optimal DTR estimated by AMOL and Q-learning, we present
the normalized coefficients of the baseline and stage 1 tailoring variables in Figure 5. Based
on AMOL, the most significant baseline tailoring variable is medication prior to enrollment,
while all the other variables had negligible magnitudes (< 0.0001). Q-learning also reveals
prior medication as the most important variable but also yields additional small effects for
some other variables. Interestingly, for stage 2, both methods identify adherence to stage 1
treatment as the most important tailoring variable. The estimated rule from AMOL suggests
that children who do not have prior exposure to medication before the trial should start with
behavioral modification, while those who have prior medication exposure should start with
the study medication. For stage 2, children who adhere to their initial treatment but do not
respond should continue with an intensified version of the same treatment, while children who
do not adhere should augment their initial assignment with the alternative treatment. We
also analyze data from STAR*D study (Rush et al., 2004) and the results are presented in the
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Figure 3: Design of Adaptive Pharmacological Behavioral Treatments for Children with ADHD
Trial; BMOD, behavior modification; MEDS, low-dose medication.
Online Supplementary Material.
6 Discussion
In this work, we proposed AMOL to estimate DTRs through doubly robust augmentation
based on two popular methods: Q-learning and O-learning. Q-learning as a regression-based
approach identifies optimal DTRs through fitting parametric regression models; while the
original O-learning targets the value function directly and introduces nonparametric decision
rules through kernel functions. Proposed AMOL draws efficiency from Q-learning to improve
O-learning while maintaining consistency. In trials such as EMBARC, it is difficult to identify
apriori which variables may serve as tailoring variables for treatment response. AMOL may be
superior in such settings with large number of non-treatment-differentiating noise variables.
The appendix in a related working paper in Luedtke and van der Laan (2014) described the
idea of double robust estimation, but without explicit support vector machine implementation
or the consideration of convergence rates of the learning algorithm. It would be interesting to
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Figure 4: Mean and empirical standard error of the value function (school performance score,
higher score desirable) based on 100 repetitions of 2-fold cross validation using ADHD data
Figure 5: Normalized coefficients of the stage 1 tailoring variables (left panel) and stage 2
tailoring variables (right panel) obtained by AMOL and Q-learning
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further explore how to combine the advantages of AMOL and their super learning improving
the estimation of personalized treatment regimes.
Clinicians may be interested in ranking the most important variables to predict patient
heterogeneity to treatment. Biomarkers that could signal patients’ heterogeneous responses
to various interventions are especially useful as tailoring variables. This information can be
used to design new intervention arms in future confirmatory trials and facilitate discovering
new knowledge in medical research. Variable selection may help construct a less noisy rule
and avoid over-fitting. Although AMOL leads to a sparse DTR in the ADHD and STAR*D
examples, a future research topic is to investigate methods that perform automatic variable
selection in the outcome-weighted learning framework.
Our current framework can easily handle nonlinear decision functions by using nonlinear
kernels. Such kernels may improve performance for high-dimensional correlated tailoring vari-
ables. Kernel techniques perform automatic dimension reduction through the kernel functions
turning a p × p matrix into an n × n matrix, where p is the number of feature variables and
n is the sample size. In addition, it is possible to consider other kinds of decision functions
such as decision trees to construct DTRs that are highly interpretable.
In clinical studies, combinations of various outcomes may be of interest (Teixeira-Pinto,
Siddique, Gibbons, & Normand, 2009). For example, alleviation of symptoms may be con-
sidered in conjunction with increased quality of life and functioning, time to response, and
reduction of side effect. Therefore, it may be insufficient to represent all information in a
one-dimensional outcome. It is worth exploring machine learning methods to deal with multi-
dimensional responses or multi-dimensional value functions. Lastly, in some clinical studies
there may be more than two treatment options at a given stage. AMOL can be extended to
handle more than two treatment groups through multi-category classification.
APPENDIX
Proof of Theorem 3.2.
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We let
V(f ; g, s) = E
[ |g(R,A,H)− s(H)|
pi(A,H)
I(Asign(g(R,A,H)− s(H)) = sign(f(H)))
]
,
and
Rφ(f ; g, s) = E
[ |g(R,A,H)− s(H)|
pi(A,H)
(1− Asign(g(R,A,H)− s(H))f(H))+
]
.
Clearly, if f˜ maximizes V(f ; g∗, s∗), following the same argument in Section 2.2, we know f˜
maximizes E [(g∗(R,A,H)− s∗(H))I(A = sign(f(H)))/pi(A,H)] which is equivalent to
E [g∗(R,A,H)I(A = sign(f(H)))/pi(A,H)]− E[s∗(H)].
Since E[g∗(R,A,H)|A,H] = E[R|A,H]. We conclude that f˜ maximizes
E [RI(A 6= sign(f(H))/pi(A,H)] ,
i.e., V(f). This implies that f˜ gives the same treatment rule as f ∗. We define fˇ to maximize
V(f ; ĝ, ŝ). Consider the event {E[|ĝ(R,A,H)− g∗(R,A,H)|+ |ŝ(H)− s∗(H)|] ≤ c′τ/nβ} which
has probability at least 1− e−τ/2. In this event, we obtain
V(f ∗)− V(f̂) = V(f ∗; , g∗, s∗)− V(f̂ ; g∗, s∗)
≤ V(f ∗; ĝ, ŝ)− V(f̂ ; ĝ, ŝ) + cτn−β
≤ V(fˇ ; ĝ, ŝ)− V(f̂ ; ĝ, ŝ) + cτn−β
≤ Rφ(f̂ ; ĝ, ŝ)−Rφ(fˇ ; ĝ, ŝ) + cτn−β,
where the last step follows the excess risk result from Theorem 3.2 of Zhao et al. (2012) but the
weight is taken to be |ĝ(R,A,H)− ŝ(H)|/pi(A,H). The remaining proof then follows the same
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arguments in the proof of Theorem 3.4 in Zhao et al. (2012) except that their loss function
is replaced by |ĝ(R,A,H)− ŝ(H)|I(Asign(ĝ(R,A,H)− ŝ(H)) = sign(f(H)))/pi(A,H). Using
their result, we obtain with at least probability 1− e−τ/2,
Rφ(f̂ ; ĝ, ŝ)−Rφ(ˇ;ĝ, ŝ) ≤ c
[
λ−2/(2+ν)+(2−ν)(1+δ)/[(2+ν)(1+q)]n n
−2/(2+ν) + τ/(nλn) + λq/(q+1)n
]
.
Combining the above results, we obtain Theorem 3.2.
Proof of Theorem 3.3.
For abbreviation, we let Ak =
{
Aj = D∗j (Hj), j ≥ k
}
and p(Ak) =
∏
j≥k pij(Aj, Hj). By
sequential conditional expectations, we obtain E[
∏K
j=k I(Ak)/p(Ak)|Hk] = 1. Furthermore,∑K
j=k Rj = Qk when Aj = D∗j (Hj), j ≥ k. Thus, the unbiasedness holds. To show the second
part of the theorem, we note that its conditional variance given Hk is
V ar(
I(Ak)
p(Ak)Qk
∣∣∣Hk)− 2E [I(Ak)
p(Ak)
I(Ak)− p(Ak)
p(Ak) (Qk − E[Qk|Hk])|Hk
]
(µ(Hk)− E[Qk|Hk])
+V ar(
I(Ak)
p(Ak) |Hk)(µ(Hk)− E[Qk|Hk])
2.
Thus it is clear that this variance is minimized when we choose
µ(Hk) = E[Qk|Hk] +
{
V ar(
I(Ak)
p(Ak) |Hk)
}−1
E
[
I(Ak)
p(Ak)
1− p(Ak)
p(Ak) (Qk − E[Qk|Hk])|Hk
]
.
When pij(Aj, Hj) is constant for any j,
E
[
I(Ak)
p(Ak)
1− p(Ak)
p(Ak) (Qk − E[Qk|Hk])|Hk
]
=
1− p(Ak)
p(Ak) E [(Qk − E[Qk|Hk])|Hk] = 0.
Then the optimal µ(Hk) = E[Qk|Hk].
Proof of Theorem 3.4
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We define a conditional value function at stage k as
Uk(Hk+1; fk+1, ..., fK) = E
[∑K
j=k+1RjΠ
K
j=k+1I(Aj = sign(fj(Hj)))
ΠKj=k+1pij(Hj, Aj)
∣∣∣HK+1] .
Clearly, Vk(fk, ..., fK) = E [I(Ak = sign(fk(Hk)))Uk(Hk+1; fk+1, ..., fK)/pik(Ak, Hk)] . In AMOL
for the K-stage trial, f̂k minimizes
Rφ,n(f ; f̂k+1, ..., f̂K) = n−1
n∑
i=1
|Ŵik|(1− Aiksign(Ŵik)f(Hik))+ + λnk‖f‖2,
where ŴiK = RiK/piK(AiK , HiK) and for k < K,
Ŵik =
1
pik(Aik, Hik)
[
I(Ai,k+1f̂k+1(Hi,k+1) > 0, ..., Ai,K f̂K(Hi,K) > 0)(
∑K
j=k Rij)∏K
j=k+1 pij(Aij, Hij)
−I(Ai,k+1f̂k+1(Hi,k+1) > 0, ..., Ai,K f̂K(Hi,K) > 0)−
∏K
j=k+1 pij(Aij, Hij)∏K
j=k+1 pij(Aij, Hij)
×ĝk(Hi,k+1) +Rik − ŝk(Hik)] ,
where ĝk(Hk+1) is the estimator for the predicted optimal value function obtained from Q-
learning.
At the final stage, f̂K is essentially the estimated rule from a single-stage AMOL, so from
Theorem 3.2, we have
P (VK(f ∗K)− VK(f̂K) ≤ K(τ)) ≥ 1− e−τ , (A.1)
where K(τ) = c
[
n−βK + λ
− 2
2+VK +
(2−VK )(1+δK )
(2+VK )(1+qK )
n n
− 2
2+VK + τ/(nλnK) + λ
qK
qK+1
nK
]
for some constant
c and the exponent qK in the GNE condition for the K-th stage. Furthermore, we obtain
‖f̂K‖ ≤ c/
√
λnK for some constant with at least probability 1− e−τ/4.
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For k = K − 1, we note
VK−1(f ∗K−1, f ∗K)− VK−1(f̂K−1, f̂K)
≤ VK−1(f ∗K−1, f ∗K)− VK−1(f ∗K−1, f̂K) + VK−1(f ∗K−1, f̂K)− VK−1(f̂K−1, f̂K).
On the other hand, since
UK−1(HK ; f ∗K) ≥ UK−1(Hk; f̂K)
and
E
[
I(AKf
∗
K(HK) > 0)− I(AK f̂K(HK) > 0)
piK(AK , HK)
|HK
]
= 0,
we have
VK−1(f ∗K−1, f ∗K)− VK−1(f ∗K−1, f̂K)
= E
[
I(AK−1 = sign(f ∗K−1))
piK−1(AK−1, HK−1)
{
UK−1(HK ; f ∗K)− UK−1(HK ; f̂K)
}]
≤ c−10 E
[{
UK−1(HK ; f ∗K)− UK−1(HK ; f̂K)
}]
= c−10
{
VK(f ∗K)− VK(f̂K)
}
,
where c0 is the lower bound for pik(ak, hk) for k = 1, ..., K. Hence,
VK−1(f ∗K−1, f ∗K)− VK−1(f̂K−1, f̂K)
≤ c−10
{
VK(f ∗K)− VK(f̂K)
}
+ VK−1(f ∗K−1, f̂K)− VK−1(f̂K−1, f̂K). (A.2)
We define
f˜K−1 = argmaxfVK−1(f, f̂K).
Then (A.2) gives
VK−1(f ∗K−1, f ∗K)− VK−1(f̂K−1, f̂K)
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≤ c−10
{
VK(f ∗K)− VK(f̂K)
}
+
{
VK−1(f˜K−1, f̂K)− VK−1(f̂K−1, f̂K)
}
. (A.3)
Note that the second term on the right-hand side of (A.3) is essentially the value loss due to
using f̂K−1 if we restrict to the population where AK = sign(f̂K). Thus, if we let
ω(f, g, s) =
1
piK−1(AK−1, HK−1)
{
I(AK = sign(f(HK)))(RK)
−I(AK = sign(f(HK)))− piK(AK , HK)
piK(AK , HK)
g(HK) +RK−1 − s(HK−1)
}
,
then for any f ,
E[ω(f̂K , g
∗
K−1, s
∗
K−1)I(AK−1f(HK−1) > 0)]
= E
[
I(AK−1f(HK−1) > 0, AK = sign(f̂K(HK))(RK−1 +RK)
piK−1(AK−1, HK−1)
]
,
and thus
0 ≤ VK−1(f˜K−1, f̂K)− VK−1(f̂K−1, f̂K)
= E[ω(f̂K , g
∗
K−1, s
∗
K−1)I(AK−1f˜K−1(HK−1) > 0)]
−E[ω(f̂K , g∗K−1, s∗K−1)I(AK−1f̂K−1(HK−1) > 0)]
= E[|ω(f̂K , g∗K−1, s∗K−1)|I(AK−1sign(ω(f̂K , g∗K−1, s∗K−1))f̂K−1(HK−1) ≤ 0)]
−E[|ω(f̂K , g∗K−1, s∗K−1)|I(AK−1sign(ω(f̂K , g∗K−1, s∗K−1))f˜K−1(HK−1) ≤ 0)].
Moreover, using the excess risk result in Theorem 3.2 of Zhao et al. (2012) (also see Barlett
et al. 2006), we obtain
VK−1(f˜K−1, f̂K)− VK−1(f̂K−1, f̂K) ≤ Rφ(f̂K−1; f̂K , g∗K−1, s∗K−1)−Rφ(f˜K−1; f̂K , g∗K−1, s∗K−1),
(A.4)
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where
Rφ(f ; fK , gK−1, sK−1) = E[|ω(fK , gK−1, sK−1)|(1− AK−1sign(ω(fK , gK−1, sK−1))f(HK−1))+].
Consider the set
A = {E[|ĝK−1(HK)− g∗K−1(HK)|+ |ŝK−1(HK−1)− s∗(HK−1)|] ≤ c1τ/nβK−1} .
According to (C.2), P (A) > 1− e−τ/2. Furthermore, on this set, it is clear that
sup
f
|Rφ(f ; f̂K , g∗K−1, s∗K−1)−Rφ(f ; f̂K , ĝK−1, ŝK−1)|
≤ c2E[|ĝK−1(HK)− g∗K−1(HK)|+ |ŝK−1(HK−1)− s∗(HK−1)|]
+c2E[|ω(f̂K , g∗K−1, s∗K−1)||sign(ω(f̂K , ĝK−1, ŝK−1))− sign(ω(f̂K , g∗K−1, s∗K−1))|]
for some constant c2. Since if sign(ω(f̂K , ĝK−1, ŝK−1))− sign(ω(f̂K , g∗K−1, s∗K−1) 6= 0 then
|ω(f̂K , g∗K−1, s∗K−1)| ≤ |ω(f̂K , g∗K−1, s∗K−1)− ω(f̂K , ĝK−1, ŝK−1)|
≤ c2
{|ĝK−1(HK)− g∗K−1(HK)|+ |ŝK−1(HK−1)− s∗K−1(HK−1)|} ,
and we have
sup
f
|Rφ(f ; f̂K , g∗K−1, s∗K−1)−Rφ(f ; f̂K , ĝK−1, ŝK−1)| ≤ c3τ/nβK−1
for some constant c3.
Therefore, combining the results from (A.1)–(A.4), we obtain that by re-defining a constant
c in K(τ), with at least 1− 3e−τ/2 probability,
VK−1(f̂K−1, f̂K) ≥ VK−1(f ∗K−1, f ∗K)− c−10 K(τ)− c
τ
nβK−1
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−
{
Rφ(f̂K−1; f̂K , ĝK−1, ŝK−1)−Rφ(f˜K−1; f̂K , ĝK−1, ŝK−1)
}
. (A.5)
Hence, to prove the theorem for K − 1, it suffices to derive a stochastic bound for the last
term in the right-hand side of (A.5).
Note that this term is the excess risk if we treat Rφ(f ; f̂K , ĝK−1, ŝK−1) as the loss func-
tion. Clearly, f˜K−1 is the minimizer and based on the definition of f̂K−1, f̂K−1 minimizes its
corresponding empirical version with regularization:
Rφn(f ; f̂K , ĝK−1, ŝK−1) ≡ n−1
n∑
i=1
|ω̂i|(1− Ai,K−1sign(ω̂i)f(Hi,K−1))+ + λn,K−1‖f‖,
where
ω̂i =
1
piK−1(Ai,K−1, Hi,K−1)
{
(Ri,K)I(AiK = sign(f̂K(HiK)))
−I(AiK = sign(f̂K(HiK)))− piK(AiK , HiK)
piK(AiK , HiK)
ĝK−1(HiK) +Ri,K−1 − ŝK−1(Hi,K−1)
}
.
The derivation of the stochastic bound follows the same arguments used in the proof of The-
orem 3.4 in Zhao et al. (2012). The only difference is that the loss function corresponding to
Rφ, i.e.,
l(f) ≡ |ω(f̂K , ĝK−1, ŝK−1)|(1− AK−1sign(ω(f̂K , ĝK−1, ŝK−1))f(HK−1))+,
depends on f̂K and ĝK−1 as well as ŝK−1. Since the latter are all bounded by cτ/
√
λn,K
with probability at least 1− e−τ/8 for a large c, the -entropy number for l(f) is bounded by
c−vσ(1−v/2)(1+δ)n for any v ∈ (0, 2) and δ > 0. Therefore, from Theorem 5.6 in Steinwart and
Scovel (2007) and using conditions (C.1) and (C.3), we conclude that with at least probability
1− e−τ/2,
Rφ(f̂K−1; f̂K , ĝK−1, ŝK−1)−Rφ(f˜K−1; f̂K , ĝK−1, ŝK−1)
≥ c
[
λ
− 2
2+VK−1+
(2−VK−1)(1+δK−1)
(2+VK−1)(1+qK−1)
n,K−1 n
− 2
2+VK−1 +
τ
nλn,K−1
+ λ
qK−1
qK−1+1
n,K−1
]
. (A.6)
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Finally, combining (A.5) and (A.6) yields
P
{
VK−1(f ∗K−1, f ∗K)− VK−1(f̂K−1, f̂K) ≤ c−10 n,K(τ) + n,K−1(τ)
}
≥ 1− 2eτ .
By repeating the above proofs from stage K − 2 through stage 1, we obtain the result in
Theorem 3.4.
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